ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v10i1.588ppharm-252Research ArticleДИСКУССИОННЫЕ ВОПРОСЫ ФАРМАКОТЕРАПИИDEBATABLE ISSUES OF PHARMACOTHERAPYТЕРАТОГЕННЫЕ СВОЙСТВА ЛЕКАРСТВ. ИСТОРИЯ ВОПРОСАTERATOGENIC PROPERTIES OF DRUGS. BACKGROUND INFORMATIONИвановаА. А.IvanovaA. A.

postgraduate student at the faculty of medicine, St. Petersburg State University

ivanova@guap.ruМихайловА. В.MikhailovA. V.КолбинА. С.KolbinA. S.Санкт-Петербургский государственный университет, Российская ФедерацияРоссияSt. Petersburg State UniversityRussian FederationА.А. Иванова1,2, 3, 4 1 Санкт-Петербургский государственный университет, Российская Федерация Санкт-Петербургский ГБУЗ «Родильный дом № 17», Российская Федерация; Северо-Западный государственный медицинский университет им. И.И. Мечникова, Санкт-Петербург, Российская ФедерацияRussian FederationSFHI «Maternity Hospital № 17», St. Petersburg, Russian Federation; Mechnikov North-West State Medical University, St. Petersburg, Russian FederationRussian FederationРегиональный центр мониторинга и безопасности лекарственных средств, Санкт-Петербург, Российская ФедерацияRussian FederationRegional Centre for Drug Monitoring and Safety, St. Petersburg, Russian FederationRussian Federation201313022013101Педиатрическая фармакология4653Copyright © Иванова А.А., Михайлов А.В., Колбин А.С., 20132013Иванова А.А., Михайлов А.В., Колбин А.С.Ivanova A.A., Mikhailov A.V., Kolbin A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/252

The article presents the most significant steps in the development of ideas about drugs’ effects on fetus. It features the thalidomide tragedy and features of thalidomide teratogenic properties, as well as data on thalidomide syndrome prevention relevance in the 21st century. The article covers teratogenesis principles and gives information about the discovery of teratogenic properties and their manifestation in several other major teratogens: retinoids, carbamazepine, valproic acid, diethylstilbestrol.

беременные женщинытератогенные свойствалекарственные средствапринципы тератогенезаталидомидретиноидыкарбамазепинвальпроевая кислотадиэтилстильбэстролpregnant womenteratogenic propertiesdrugsteratogenesis principlesthalidomideretinoidscarbamazepinevalproic aciddiethylstilbestrolReferencesGuidance for industry reproductive and developmental toxities — integrating study results to assess concerns. U. S. Department of health and human services, food and drug administration, center for drug evalution and research (CDER). Pharmacology and Toxicology. 2011 Sept. 20 p.Guidance for industry reproductive and developmental toxities — integrating study results to assess concerns. U. S. Department of health and human services, food and drug administration, center for drug evalution and research (CDER). Pharmacology and Toxicology. 2011 Sept. 20 p.Шефер К., Шпильманн Х., Феттер К. Лекарственная терапия в период беременности и лактации. Пер. с нем. под ред. Б. К. Романова. М.: Логосфера. 2010. 768 с.Schaefer C., Spielmann H., Vetter K. Lekarstvennaya terapiya v period beremennosti i laktatsii. Per. s nem. pod red. B.K. Romanova [Drug Therapy during Pregnancy and Lactation. Translated from German, edited by B.K. Romanov]. Moscow, Logosfera, 2010. 768 p.Shaefer C., Peters P., Miller R. C. Drugs during pregnancy and lactation. Treatment options and risk assessment. Second edition. Elsevier. 2007. 875 р.Shaefer C., Peters P., Miller R. C. Drugs during pregnancy and lactation. Treatment options and risk assessment. Second edition. Elsevier, 2007. 875 р.Астахова А. В., Лепахин В. К. Беременность и лекарства. В кн.: Лекарства. Неблагоприятные побочные реакции и контроль безопасности. Безопасность лекарств и фармаконадзор. 2009; 2: 3–20.Astakhova A.V., Lepakhin V.K. Pregnancy and medication. In book: Medicines. Adverse drug reactions well as a monitoring security. Bezopasnost' lekarstv i farmakonadzor = Drug safety and pharmacovigilance. 2009; 2: 3–20.Шер С. А. Тератогенное воздействие лекарственных средств на организм будущего ребенка на этапе внутриутробного развития. Педиатрическая фармакология. 2011; 8 (6): 57–60.Sher S.A. Teratogenic effects of drugs on the body of the child in utero. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2011; 8 (6): 57–60.Dally A. Thalidomide: was the tragedy preventable? Lancet. 1998; 351: 1197– 9.Dally A. Thalidomide: was the tragedy preventable? Lancet. 1998; 351: 1197– 9.Кириллова И. А., Кравцова Г. И., Кручинский Г. В. и др. Тера тология человека. Руководство для врачей. Под ред. Г. И. Лазюка. 2-е изд., перераб. и доп. М.: Медицина. 1991. 480 с.: ил.Kirillova I.A., Kravtsova G.I., Kruchinskii G.V. et al. Teratologiya cheloveka. Rukovodstvo dlya vrachei. Pod red. G. I. Lazyuka. 2-e izd., pererab. i dop. il. [Human Teratology. Guide for Physicians. Edited by G.I. Lazyuk. 2nd ed., rev. and enl., illustrated]. Moscow, Meditsina, 1991. 480 p.Schumacher G. H. Teratology in cultural documents and today. Ann Anat. 2004; 186 (5–6): 539–46.Schumacher G. H. Teratology in cultural documents and today. Ann. Anat. 2004; 186 (5–6): 539–46.Garfield E. Teratology literature and the thalidomide controversy. Essays of an Information Scientist. 1986; 9: 404–412.Garfield E. Teratology literature and the thalidomide controversy. Essays of an Information Scientist. 1986; 9: 404–412.Friedman J. M. The principles of teratology: are they still true? Birth Defects Res A Clin Mol Teratol. 2010; 88 (10): 766–8.Friedman J. M. The principles of teratology: are they still true? Birth. Defects Res. A Clin. Mol. Teratol. 2010; 88 (10): 766–768.Squier S. M. Poultry science, chicken culture: a partial alphabet. Rutgers University Press, 2011. Р. 84.Squier S. M. Poultry science, chicken culture: a partial alphabet. Rutgers University Press, 2011. Р. 84.Stephens T., Brynner R. Dark remedy: the impact of thalidomide and its revival as a vital medicine. USA: Basic Books. 2001. 240 р.Stephens T., Brynner R. Dark remedy: the impact of thalidomide and its revival as a vital medicine. USA, Basic Books, 2001. 240 р.Greek R., Shanks N., Rice M. J. The history and implications of testing thalidomide on animals. The Journal of Philosophy, Scince & Law. 2011; 11. URL: http://www.miami.edu/ethics/jpslGreek R., Shanks N., Rice M. J. The history and implications of testing thalidomide on animals. The Journal of Philosophy, Scince & Law. 2011; 11. Available at: http://www.miami.edu/ethics/jpslWhipple G. H. Pregnancy and chloroform anesthesia: a study of the maternal, placental, and fetal tissues. J Exp Med. 1912; 15 (3): 246–258.Whipple G. H. Pregnancy and chloroform anesthesia: a study of the maternal, placental, and fetal tissues. J. Exp. Med. 1912; 15 (3): 246–258.Wilson J. G. The evolution of teratological testing. Teratology. 1979; 20 (2): 205–211.Wilson J. G. The evolution of teratological testing. Teratology. 1979; 20 (2): 205–211.Briggs G. G., Freeman R. K., Yaffee S. J. Drugs in pregnancy and lactation. Eight edition. Philadelphia: LippincottWilliams & Wilkins. 2008. 2217 p.Briggs G. G., Freeman R. K., Yaffee S. J. Drugs in pregnancy and lactation. Eight edition. Philadelphia, LippincottWilliams & Wilkins, 2008. 2217 p.Vianna F. S., Lopez-Camelo J. S., Leite J. C. et al. Epidemiological surveillance of birth defects compatible with thalidomide embryopathy in Brazil. PLoS One. 2011; 6 (7): e21735.Vianna F. S., Lopez-Camelo J. S., Leite J. C. et al. Epidemiological surveillance of birth defects compatible with thalidomide embryopathy in Brazil. PLoS One. 2011; 6 (7): e21735.Kalter H. Teratology in the 20th century: environmental causes of congenital malformations in humans and how they were established. Neurotoxicol Teratol. 2003; 25 (2): 131–282.Kalter H. Teratology in the 20th century: environmental causes of congenital malformations in humans and how they were established. Neurotoxicol. Teratol. 2003; 25 (2): 131–282.Avorn J. Learning about the safety of drugs — a half-century of evolution. N Engl J Med. 2011; 365: 2151–2153.Avorn J. Learning about the safety of drugs — a half-century of evolution. N Engl J Med. 2011; 365: 2151–2153.McBride W. G. Thalidomide and congenital abnormalities. Lancet. 1961; 2: 358.McBride W. G. Thalidomide and congenital abnormalities. Lancet. 1961; 2: 358.Lenz W. Thalidomide and congenital abnormalities. Lancet. 1962; 1: 45.Lenz W. Thalidomide and congenital abnormalities. Lancet. 1962; 1: 45.Klingberg M. A. An epidemiologist's journey from typhus to thalidomide, and from the Soviet Union to Seveso. JLL Bulletin: Commentaries on the history of treatment evaluation (www.jameslindlibrary.org). 2010.Klingberg M. A. An epidemiologist's journey from typhus to thalidomide, and from the Soviet Union to Seveso. JLL Bulletin: Commentaries on the history of treatment evaluation (www.jameslindlibrary.org). 2010.Zheng C. F., Xu J. H., Huang Y. et al. Treatment of pediatric refractory Crohn’s disease with thalidomide. World J Gastroenterol. 2011; 17 (10): 1286–1291.Zheng C. F., Xu J. H., Huang Y. et al. Treatment of pediatric refractory Crohn’s disease with thalidomide. World J. Gastroenterol. 2011; 17 (10): 1286–1291.Методические рекомендации по изучению общетоксического действия фармакологических средств. Утверждены Управлением государственного контроля лекарственных средств и медицинской техники Минздрава России 29 декабря 1997 г.Metodicheskie rekomendatsii po izucheniyu obshchetoksicheskogo deistviya farmakologicheskikh sredstv. Utverzhdeny Upravleniem gosudarstvennogo kontrolya lekarstvennykh sredstv i meditsinskoi tekhniki Minzdrava Rossii 29 dekabrya 1997 g. [Guidelines for the Study of the General Toxicity of Pharmacological Agents. Approved by the Office of the State Control of Medicines and Medical Equipment of Russian Ministry of Health dated December 29, 1997].Ryon M. G., Sawhney D. S. Scientific rationale for the selection of toxicity testing methods II. Teratology, immunotoxicology, and inhalation toxicology. United States Environmental Protection Agency. Washington DC. 1985. 253 p.Ryon M. G., Sawhney D. S. Scientific rationale for the selection of toxicity testing methods II. Teratology, immunotoxicology, and inhalation toxicology. United States Environmental Protection Agency, Washington DC, 1985. 253 p.Lo W. Y., Friedman J. M. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol. 2002; 100 (3): 465–73.Lo W. Y., Friedman J. M. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol. 2002; 100 (3): 465–73.Стриженок Е. А., Гудков И. В., Страчунский Л. С. Применение лекарственных средств при беременности: результаты многоцентрового фармакоэпидемиологического исследования. Клин. микробиол. антимикроб. химиотер. 2007; 9 (2): 162–175.Strizhenok E.A., Gudkov I.V., Strachunskii L.S. pplication of drugs during pregnancy: results of a multicenter pharmacoepidemiological study. Klin. mikrobiol. antimikrob. khimioter. = Clinical microbiology and antimicrobial chimiotherapy. 2007; 9 (2): 162–175.Федеральный закон Российской Федерации от 12 апреля 2010 г. № 61-ФЗ ≪Об обращении лекарственных средств≫. Ст. 43, п. 6.Federal'nyi zakon Rossiiskoi Federatsii ot 12 aprelya 2010 g. № 61-FZ «Ob obrashchenii lekarstvennykh sredstv». St. 43, p. 6 [Federal Law dated April 12, 2010 № 61-FZ "On Circulation of Medicines". Art. 43, p. 6].Reviewer guidance evaluating the risk of drug exposure in human pregnancies. U. S. Department of health and human services, food and drug administrtion, center for drug evaluation and research (CDER). Center for Biologics Evaluation and Research (CBER). 2005. 28 р.Reviewer guidance evaluating the risk of drug exposure in human pregnancies. U. S. Department of health and human services, food and drug administrtion, center for drug evaluation and research (CDER). Center for Biologics Evaluation and Research (CBER). 2005. 28 р.Загородникова К. А., Бурбелло А. Т., Покладова М. В. Безопасность лекарств и фармаконадзор у беременных — отталидомидовой трагедии≫ до наших дней. Ремедиум. 2012; 8 (186): 15–22.Zagorodnikova K.A., Burbello A.T., Pokladova M.V. Safety of medicines and pharmacovigilance in pregnant women - from "talidomidovoy tragedy" to the present day. Remedium = Remedium. 2012; 8 (186): 15–22.Jelinek R. The contribution of new findings and ideas to the old principles of teratology. Reprod Toxicol. 2005; 20 (3): 295–300.Jelinek R. The contribution of new findings and ideas to the old principles of teratology. Reprod Toxicol. 2005; 20 (3): 295–300.Валькович Э. И. Тератогенез и тератогенность. Педиатр. 2010; 1: 13–15.Val'kovich E.I. Teratogenesis and teratogenicity. Pediatr = Pediatrician. 2010; 1: 13–15.van Gelder M. M., van Rooij I. A., Miller R. K. et al. Teratogenic mechanisms of medical drugs. Hum Reprod Update. 2010; 16 (4): 378–94.van Gelder M. M., van Rooij I. A., Miller R. K. et al. Teratogenic mechanisms of medical drugs. Hum. Reprod Update. 2010; 16 (4): 378–94.Эндрю Четли. Проблемные лекарства. Landmark Ltd. 1998. 256 с. (электронная версия книги на официальном сайте www.antibiotic.ru).Chetley A. Problemnye lekarstva [Problem Drugs]. Landmark Ltd, 1998. 256 p. Available at official web site: www.antibiotic.ru.Hormonally active agents in the environment. Committee on hormonally active agents in the environment, board on environmental studies and toxicology, commission on life scinces, national research council. National academy press. 1999. 435 р.Hormonally active agents in the environment. Committee on hormonally active agents in the environment, board on environmental studies and toxicology, commission on life scinces, national research council. National academy press, 1999. 435 р.Scientific frontiers in developmental toxicology and risk assessment. Committee on developmental toxicology, board on environmental studies and toxicology, national research council. Washington, DC: National Academies Press. 2000. 354 р.Scientific frontiers in developmental toxicology and risk assessment. Committee on devel-opmental toxicology, board on environmental studies and toxicology, national research council. Washington, DC, National Academies Press, 2000. 354 р.Завидова С.С., Намазова-Баранова Л.С., Тополянская С.В. Клинические исследования лекарственных препаратов в педиатрии: проблемы и достижения. Педиатрическая фармакология. 2010; 7 (1): 6–14.Zavidova S.S., Namazova-Baranova L.S., Topolyanskaya S.V. Clinical studies of drugs in pediatrics: challenges and achievements. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2010; 7 (1): 6–14.

The authors declare that there are no conflicts of interest present.